Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Paragon Care Limited ( (AU:PGC) ) has provided an update.
Paragon Care Limited’s Annual Report for 2025 highlights its position as a diversified healthcare leader in the Asia Pacific, emphasizing its commitment to simplifying and enhancing healthcare accessibility. The report underscores the company’s strategic growth following its merger with Clifford Hallam and its dedication to environmental, social, and governance (ESG) principles, which are crucial for its stakeholders and industry positioning.
The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
More about Paragon Care Limited
Paragon Care Limited is a leading healthcare distributor and manufacturer in the Asia Pacific region. The company offers a wide range of products including pharmaceuticals, capital equipment, diagnostics, medical consumables, devices, and complementary medicines. Established in Australia in 1918, Paragon Care has grown significantly, notably through its 2024 merger with Clifford Hallam, and is now an ASX-listed entity focused on making healthcare more accessible across the region.
Average Trading Volume: 418,090
Technical Sentiment Signal: Sell
Current Market Cap: A$471.8M
Learn more about PGC stock on TipRanks’ Stock Analysis page.